AU2013334138B2 - Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome - Google Patents

Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome Download PDF

Info

Publication number
AU2013334138B2
AU2013334138B2 AU2013334138A AU2013334138A AU2013334138B2 AU 2013334138 B2 AU2013334138 B2 AU 2013334138B2 AU 2013334138 A AU2013334138 A AU 2013334138A AU 2013334138 A AU2013334138 A AU 2013334138A AU 2013334138 B2 AU2013334138 B2 AU 2013334138B2
Authority
AU
Australia
Prior art keywords
compound
salt
acid
mmol
usher
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013334138A
Other languages
English (en)
Other versions
AU2013334138A1 (en
Inventor
Roland Werner BURLI
William Rameshchandra Krishna ESMIEU
William Edward HARTE
Christopher James Lock
Karine Fabienne MALAGU
Andrew Pate Owens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Usher III Initiative Inc
Original Assignee
Usher III Initiative Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Usher III Initiative Inc filed Critical Usher III Initiative Inc
Publication of AU2013334138A1 publication Critical patent/AU2013334138A1/en
Application granted granted Critical
Publication of AU2013334138B2 publication Critical patent/AU2013334138B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2013334138A 2012-10-25 2013-10-25 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome Active AU2013334138B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261718593P 2012-10-25 2012-10-25
US61/718,593 2012-10-25
US201361775376P 2013-03-08 2013-03-08
US61/775,376 2013-03-08
PCT/US2013/066938 WO2014066835A1 (en) 2012-10-25 2013-10-25 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome

Publications (2)

Publication Number Publication Date
AU2013334138A1 AU2013334138A1 (en) 2015-05-07
AU2013334138B2 true AU2013334138B2 (en) 2017-07-27

Family

ID=50545355

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013334138A Active AU2013334138B2 (en) 2012-10-25 2013-10-25 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome

Country Status (10)

Country Link
EP (1) EP2912038B1 (https=)
JP (1) JP6290910B2 (https=)
AU (1) AU2013334138B2 (https=)
CA (1) CA2889537C (https=)
ES (1) ES2693166T3 (https=)
IL (1) IL238287B (https=)
PL (1) PL2912038T3 (https=)
TR (1) TR201816028T4 (https=)
WO (1) WO2014066835A1 (https=)
ZA (1) ZA201502654B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012148994A1 (en) 2011-04-25 2012-11-01 Usher Iii Initiative Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
WO2014066836A1 (en) * 2012-10-25 2014-05-01 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
IL299695A (en) 2020-07-09 2023-03-01 Usher Iii Initiative Inc Treatment of cancer, inflammatory diseases and autoimmune diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012148994A1 (en) * 2011-04-25 2012-11-01 Usher Iii Initiative Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60232669D1 (de) * 2001-04-30 2009-07-30 Vertex Pharma Inhibitoren von gsk-3 und kristallstrukturen von gsk-3beta-protein und -proteinkomplexen
US7812166B2 (en) * 2004-10-29 2010-10-12 Abbott Laboratories Kinase inhibitors
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
US20100331297A1 (en) * 2007-11-07 2010-12-30 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
TWI546290B (zh) * 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
WO2014066836A1 (en) * 2012-10-25 2014-05-01 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012148994A1 (en) * 2011-04-25 2012-11-01 Usher Iii Initiative Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome

Also Published As

Publication number Publication date
JP6290910B2 (ja) 2018-03-07
IL238287A0 (en) 2015-06-30
ES2693166T3 (es) 2018-12-07
EP2912038A1 (en) 2015-09-02
CA2889537C (en) 2017-12-12
EP2912038B1 (en) 2018-08-15
JP2015535256A (ja) 2015-12-10
IL238287B (en) 2018-07-31
WO2014066835A1 (en) 2014-05-01
PL2912038T3 (pl) 2019-02-28
CA2889537A1 (en) 2014-05-01
EP2912038A4 (en) 2016-04-20
ZA201502654B (en) 2016-07-27
AU2013334138A1 (en) 2015-05-07
TR201816028T4 (tr) 2018-11-21
HK1214263A1 (en) 2016-07-22

Similar Documents

Publication Publication Date Title
EP4034104B1 (en) Methods and compounds for restoring mutant p53 function
EP2911671B1 (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
US9783545B2 (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
EP2701510B1 (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
AU2013334138B2 (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome
US8765762B2 (en) Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome
HK1214263B (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
HK1195507B (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)